Cargando…

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration

PURPOSE: To determine whether gene polymorphisms of the major genetic risk factor for age-related macular susceptibility 2 (ARMS2 A69S) and the complement factor H Y402H influence the response to a variable-dosing treatment regimen with ranibizumab for age-related macular degeneration. METHODS: This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teper, Slawomir J., Nowinska, Anna, Pilat, Jaroslaw, Palucha, Andrzej, Wylegala, Edward
Formato:	Texto
Lenguaje:	English
Publicado:	Molecular Vision 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000236/ https://www.ncbi.nlm.nih.gov/pubmed/21151600

Ejemplares similares

A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for neovascular age-related macular degeneration in Poland – a brief report
por: Teper, Sławomir J., et al.
Publicado: (2012)

The Need for Treatment of Neovascular Age-Related Macular Degeneration: A Study Based on the Polish National Registry
por: Teper, Sławomir Jan, et al.
Publicado: (2022)

Peripheral Retinal Degenerations and Idiopathic Epiretinal Membrane: Analysis with Ultra-Wide-Field Scanning Laser Ophthalmoscopy
por: Ulfik-Dembska, Klaudia, et al.
Publicado: (2021)

Subthreshold Micropulse Laser for Diabetic Macular Edema: A Review
por: Sabal, Barbara, et al.
Publicado: (2022)

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography
por: Hunt, Magdalena, et al.
Publicado: (2022)

1-Year Fixed-Regimen Bevacizumab Treatment in DME-Vascular Network Image Analysis in Optical Coherence Tomography Angiography Study
por: Hunt, Magdalena, et al.
Publicado: (2022)

In Vivo Confocal Microscopy and Anterior Segment Optical Coherence Tomography Analysis of the Microcystic Keratitis
por: Dembski, Michał, et al.
Publicado: (2020)

Polygenic Risk Score Impact on Susceptibility to Age-Related Macular Degeneration in Polish Patients
por: Wąsowska, Anna, et al.
Publicado: (2022)

Idiopathic Epiretinal Membrane: Microvasculature Analysis with Optical Coherence Tomography and Optical Coherence Tomography Angiography
por: Ulfik-Dembska, Klaudia, et al.
Publicado: (2022)

Advanced Anterior Eye Segment Imaging for Ichthyosis
por: Micińska, Anna, et al.
Publicado: (2023)

How to Achieve Near-Normal Visual Acuity with Bevacizumab in Diabetic Macular Edema Patients
por: Sędziak-Marcinek, Bogumiła, et al.
Publicado: (2021)

Role of ranibizumab in management of macular degeneration
por: Singh, Rishi P, et al.
Publicado: (2007)

Seven-Year Analysis of Microbial Keratitis Tendency at an Ophthalmology Department in Poland: A Single-Center Study
por: Ulfik, Klaudia, et al.
Publicado: (2020)

Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence
por: Sędziak-Marcinek, Bogumiła, et al.
Publicado: (2021)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Treatment of age-related macular degeneration: focus on ranibizumab
por: Spitzer, Martin S, et al.
Publicado: (2008)

Acute macular edema and serous detachment on the first day after phacoemulsification surgery: A case report
por: Chlasta-Twardzik, Edyta, et al.
Publicado: (2020)

Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen
por: Mantel, Irmela, et al.
Publicado: (2014)

Optical coherence angiography: A review
por: Wylęgała, Adam, et al.
Publicado: (2016)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020)

Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Is Spectral-Domain Optical Coherence Tomography Essential for Flexible Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular Degeneration?
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Detailed corneal and genetic characteristics of a pediatric patient with macular corneal dystrophy - case report
por: Nowińska, Anna, et al.
Publicado: (2021)

Comparative Study of Anterior Eye Segment Measurements with Spectral Swept-Source and Time-Domain Optical Coherence Tomography in Eyes with Corneal Dystrophies
por: Nowinska, Anna K., et al.
Publicado: (2015)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

Influence of ranibizumab treatment on the extracellular matrix in patients with neovascular age-related macular degeneration
por: Nita, Małgorzata, et al.
Publicado: (2014)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
por: Rodríguez, Francisco Jose, et al.
Publicado: (2019)

Functional and anatomical outcome of eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab following an exit strategy regimen
por: Menke, Marcel N, et al.
Publicado: (2014)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
por: Johnston, Robert L., et al.
Publicado: (2017)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
por: Karagiannis, Dimitrios A, et al.
Publicado: (2009)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017)

Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)

Ranibizumab therapy for predominantly hemorrhagic neovascular age-related macular degeneration
por: Dikmetas, Ozlem, et al.
Publicado: (2022)

Treatment of conjunctival papilloma with topical interferon alpha-2b - case report
por: Bolek, Bartłomiej, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_chaaln2a9f2ns1mi973bcn7t96